JEMPERLI

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug JEMPERLI contains one active pharmaceutical ingredient (API):

1	Dostarlimab UNII P0GVQ9A4S5 - DOSTARLIMAB
	Dostarlimab is a humanised mAb of the IgG4 isotype that binds to PD-1 receptors and blocks the interactions of binding with its ligands PD-L1 and PD-L2. The inhibition of PD-1 pathway-mediated immune response results in reactivation of T-cell function such as proliferation, cytokine production, and cytotoxic activity. Dostarlimab potentiates T-cell responses, including anti-tumour immuno responses through blockade of PD-1 binding to PD-L1 and PD-L2.
	Read more about Dostarlimab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JEMPERLI Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FF07	Dostarlimab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1847314
ES	Centro de información online de medicamentos de la AEMPS	1211538001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	452871
FR	Base de données publique des médicaments	64849607
IL	מִשְׂרַד הַבְּרִיאוּת	9019
IT	Agenzia del Farmaco	049453018
LT	Valstybinė vaistų kontrolės tarnyba	1092482
PL	Rejestru Produktów Leczniczych	100448832